NYSE · LLY
Eli Lilly and Company
$1,429.15+$55.45 (+4.04%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · FLNA · USD
Stock price, earnings
Quote as of Oct 30, 2026, 03:27 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Filana Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Filana Therapeutics, Inc.’s next earnings report is currently expected on Oct 30, 2026, with estimated earnings per share of -$0.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Filana Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2024 | Nov 7, 2024 | -$0.58+20.55% vs estimate | $0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,429.15+$55.45 (+4.04%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$276.37+$1.17 (+0.43%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.0% below the high.
$295.87+$5.08 (+1.75%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.95% below the high.
$149.25+$2.92 (+2.0%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.89% below the high.
$407.98-$2.93 (-0.71%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.62% below the high.
$695.05-$14.13 (-1.99%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.37% below the high.
$470.13+$9.40 (+2.04%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.14% below the high.
$172.03+$6.42 (+3.88%)
Gilead Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.06% below the high.
